Maze Therapeutics spins out two new companies with Alloy and BridgeBio
The startup has become the starter.
Just under two years after bursting onto the scene with close to $200 million, Maze Therapeutics is spinning out two new companies, focusing its human genetics and functional genomics platform on ophthalmology and cardiovascular disease.
The new companies — Broadwing Bio and Contour Therapeutics — were formed from partnerships with Alloy Therapeutics and BridgeBio respectively. While the companies are keeping the financial terms under wraps, Maze says it has three programs going between the two collaborations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.